10x Genomics (TXG) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does 10x Genomics (TXG) do?
10x Genomics Inc (TXG) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures instruments, microfluidic chips, and chemical reagents for single-cell genetic sequencing. Builds integrated hardware, reagents, and software that analyze genetic activity inside individual biological cells. It is worth $7.55B on the market and sold $618.64M over the last year.
- Market cap
- $7.55B
- P/E ratio
- None (reported a loss)
- Annual sales
- $618.64M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 18, 2026
Brands and businesses behind TXG
- Chromium: Hardware instruments and reagent kits that isolate single cells for RNA sequencing assays.
- Visium: Spatial transcriptomics kits that map gene expression onto intact tissue histology slides.
- Xenium: In situ optical instruments that measure targeted RNA and protein molecules inside subcellular tissue compartments.
TXG’s flags, in plain English
Each flag is a number from 10x Genomics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 5.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 9% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 72.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Burning Cash
Losing money, profit margin of -10.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about TXG
How big is 10x Genomics?
10x Genomics’ market cap is $7.55B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $618.64M: what customers paid the company over the last year, before any costs.
What is TXG’s P/E ratio?
TXG has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with TXG?
The business depends heavily on capital spending and grants from academic institutions, which fluctuate with government funding. That is one risk on 10x Genomics’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From 10x Genomics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TXG’s filings on SEC.gov. The Margin Monkey is research, not advice.
